Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-24 @ 3:35 PM
NCT ID:
NCT00561392
Eligibility Criteria:
Inclusion Criteria:
* Males, and females not of child-bearing potential (surgically sterile or at least one year postmenopausal), of at least 50 years of age
* Probable Alzheimer's disease according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) and DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria
* MMSE (Mini-Mental State Examination) score of \> 10 and \< 26
* Patients initiating therapy for the first time with a cholinesterase inhibitor (patients prescribed both rivastigmine and memantine are allowed)
* Patients who failed to benefit from previous cholinesterase inhibitor treatment
Exclusion Criteria:
* Patients not treated according to the product monograph for rivastigmine capsules
* patients involved in a clinical trial
* Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application)
Other protocol-defined exclusion criteria applied to the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT00561392
Study Brief:
Protocol Section:
NCT00561392